Researchers conducted a study that assessed the rate of chronic pulmonary aspergillosis recurrence among patients who received oral itraconazole for 6 vs 12 months.
In this meta-analysis, researchers assessed the safety and efficacy of fluconazole compared with alternative antifungal agents for the treatment of esophageal candidiasis.
Researchers conducted a study that assessed the rate of 90-day all-cause crude mortality vs attributable mortality among patients with candida bloodstream infections.
Researchers conducted a study to determine whether gardening activities are associated with an increased risk for exposure to triazole-resistant Asperigillus fumigatus fungal spores.
Investigators conducted a study to determine the effects of quinine hydrochloride in combination with antimicrobial blue light therapy in patients with cutaneous mold infection.
Investigators conducted a study to determine outcomes following early de-escalation to fluconazole following echinocandin empirical treatment in patients with fluconazole-susceptible candidemia.
The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis.
Investigators summarized the evidence on the efficacy and adverse effects of antifungal agents in patients with hematological disease or undergoing hematopoietic stem cell transplantation.
Critically ill patients hospitalized with COVID-19 — particularly those who develop ARDS — may also experience an opportunistic aspergillosis superinfection.
The FDA has approved the sNDA for Mycamine for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.